Clinical Trials Directory

Trials / Completed

CompletedNCT06545188

Impact of Mortality Salience on Treatment Decisions

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
746 (actual)
Sponsor
Heinrich-Heine University, Duesseldorf · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The goal of this clinical trial is to learn if mortality salience has an impact on treatment decisions in urologists and patients with urological cancer. The main questions it aims to answer are: Does mortality salience lead to more aggressive treatment decisions in a) urologists and b) patients with urological cancer? Which factors predict more aggressive treatment decisions a) in urologists and b) in patients with urological cancer? Is the Fear of cancer recurrence-1 (FCR-1) in German language a valid screening tool for fear of cancer progression in patients with urological cancer? Researchers will compare a mortality salience trigger to control questions to see if mortality salience leads to more aggressive treatment decisions. Participants will: Answer the Mortality Attitudes Personality survey (MAPS) to trigger mortality salience and, in three borderline case vignettes, provide information on how likely they would be to choose a more aggressive therapy.

Detailed description

Background: Harmful overtreatment is a major problem in oncology. Unconscious fear of death (mortality salience) could increase the likelihood of a physician or patient decision in favor of aggressive therapy and thus contribute to overtreatment. Methods: Conduction of two randomized controlled trials: 1. online survey of n = 260 urological patients, 2. paper questionnaire survey of n = 260 urological cancer inpatients. Intervention group: triggering of mortality salience with two open questions on death, control group: two open questions on dental treatment. The primary endpoint is the probability of opting for aggressive treatment in three questions on a treatment decision Likert scale from 0 to 10). In both studies, the evaluation is carried out as a comparison of means using a two-sided t-test. Secondary endpoints are further factors associated with a decision in favor of aggressive therapy. Result: An increase in the probability of a decision in favor of the more aggressive therapy as a result of triggering mortality salience is expected with an effect size of d = .35. Discussion: In order to avoid harmful overtreatment due to unconscious fear of death, doctors could undergo training to deal with their existential fears - this could take place as part of communication training. For cancer patients, this confrontation can take place as part of psycho-oncology training.

Conditions

Interventions

TypeNameDescription
OTHERMortality Attitudes Personality SurveyTwo open questions about death and mortality will bei administered to trigger mortality salience
OTHERDental treatment questions (control condition)Two open questions about a dental treatment (control condition)

Timeline

Start date
2024-09-16
Primary completion
2025-11-08
Completion
2025-11-08
First posted
2024-08-09
Last updated
2025-11-24

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT06545188. Inclusion in this directory is not an endorsement.